Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00190541
Status:
COMPLETED
Last Update Posted:
2016-09-22
First Post:
2005-09-13
Brief Title:
Mesorectal Excision ME Versus ME With Lateral Node Dissection for Stage II III Lower Rectal Cancer JCOG0212
Sponsor:
Haruhiko Fukuda
Organization:
Japan Clinical Oncology Group
Study Overview
Official Title:
Mesorectal Excision With Lateral Lymph Node Dissection Versus Without Lateral Lymph Node Dissection for Clinical Stage II III Lower Rectal Cancer JCOG0212
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the of international standard operation mesorectal excision ME alone compared to Japanese standard operation ME with lateral lymph node dissection for clinical stage II III lower rectal cancer
Detailed Description:
Total mesorectal excision TME or mesorectal excision ME with lateral lymph node dissection for advanced rectal cancer is widely performed in Japan In other countries TME or ME without lateral lymph node dissection is the standard In order to determine which is the better rectal cancer surgery relapse-free survivals of these are compared as the primary endpoint
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| C000000034 | REGISTRY | UMIN-CTR | None |